TY - JOUR
T1 - Indications for Use of Drug-Coated Balloons in Coronary Intervention
T2 - Academic Research Consortium Position Statement
AU - Fezzi, Simone
AU - Serruys, Patrick W.
AU - Cortese, Bernardo
AU - Scheller, Bruno
AU - Alfonso, Fernando
AU - Jeger, Raban
AU - Colombo, Antonio
AU - Joner, Michael
AU - Shin, Eun Seok
AU - Kleber, Franz
AU - Latib, Azeem
AU - Rissanen, Tuomas T.
AU - Eccleshall, Simon
AU - Ribichini, Flavio
AU - Tao, Ling
AU - Koo, Bon Kwon
AU - Chieffo, Alaide
AU - Ge, Junbo
AU - Granada, Juan F.
AU - Stoll, Hans Peter
AU - Spaulding, Christian
AU - Cavalcante, Rafael
AU - Abizaid, Alexandre
AU - Muramatsu, Takashi
AU - Boudoulas, Konstantinos Dean
AU - Waksman, Ron
AU - Mehran, Roxana
AU - Cutlip, Donald
AU - Krucoff, Mitchell
AU - Stone, Gregg W.
AU - Garg, Scot
AU - Onuma, Yoshinobu
N1 - Publisher Copyright:
© 2025 American College of Cardiology Foundation
PY - 2025/10/14
Y1 - 2025/10/14
N2 - The Drug-Coated Balloon (DCB) Academic Research Consortium project originated from the need to overcome the lack of standardization and comparability among studies focusing on drug-coated balloon treatment. The DCB Academic Research Consortium represents a collaborative effort between academic research organizations and the most renowned interventional cardiology societies focusing on percutaneous coronary intervention in Europe, the United States, and Asia. The present consensus document provides a classification of DCB technologies, antiproliferative drugs, and types of elution and coatings. Moreover, by reviewing the available evidence on the use of DCBs for several lesion (restenosis, de novo small and large vessels, bifurcations) and clinical (acute coronary syndromes, diabetes mellitus, multivessel disease, high bleeding risk) settings, it seeks to provide reasonable suggestions for their clinical use. Last, this paper outlines the processes involved in optimal “lesion preparation” before the use of DCBs and the criteria used for assessing results following their use.
AB - The Drug-Coated Balloon (DCB) Academic Research Consortium project originated from the need to overcome the lack of standardization and comparability among studies focusing on drug-coated balloon treatment. The DCB Academic Research Consortium represents a collaborative effort between academic research organizations and the most renowned interventional cardiology societies focusing on percutaneous coronary intervention in Europe, the United States, and Asia. The present consensus document provides a classification of DCB technologies, antiproliferative drugs, and types of elution and coatings. Moreover, by reviewing the available evidence on the use of DCBs for several lesion (restenosis, de novo small and large vessels, bifurcations) and clinical (acute coronary syndromes, diabetes mellitus, multivessel disease, high bleeding risk) settings, it seeks to provide reasonable suggestions for their clinical use. Last, this paper outlines the processes involved in optimal “lesion preparation” before the use of DCBs and the criteria used for assessing results following their use.
KW - coronary artery disease
KW - drug-coated balloon
KW - percutaneous coronary intervention
UR - https://www.scopus.com/pages/publications/105016849454
UR - https://www.scopus.com/pages/publications/105016849454#tab=citedBy
U2 - 10.1016/j.jacc.2025.07.049
DO - 10.1016/j.jacc.2025.07.049
M3 - Review article
C2 - 41062231
AN - SCOPUS:105016849454
SN - 0735-1097
VL - 86
SP - 1170
EP - 1202
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 15
ER -
SDG 3 すべての人に健康と福祉を